Summary. Dyslipidemia is a risk factor for de novo occurrence of renal disease in apparently healthy population, and diabe- tes, and contributes to progressive decline of renal function in diabetic and nondiabetic kidney disease. Chronic kidney disease and dyslipidemia, frequently occurring together, are independent cardiovascular risk factors. There is a strong asso- ciation between the level of renal insufficiency and cardiovascular disease. According to available evidence, statin therapy may reduce cardiovascular risk in chronic kidney disease as well as modify its course, especially in patients with moderate impairment of renal function. However, all these findings must be examined in large-scale trials in patients with chronic renal disease and different stages of renal insufficiency. There are several on-going trials aimed at determing the role of statin therapy in this specific population, and confirming its efficacy in reducing cardiovascular risk and halting the progres- sion of chronic kidney disease.